These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 33810779)

  • 21. In Vitro Activity of Plazomicin Against Carbapenem Resistant Klebsiella pneumoniae Strains.
    Demirbas Z; Ozger HS; Suzuk-Yildiz S; Bakkaloglu Z; Dizbay M
    Clin Lab; 2022 Jun; 68(6):. PubMed ID: 35704736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin.
    Zhanel GG; Lawson CD; Zelenitsky S; Findlay B; Schweizer F; Adam H; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Expert Rev Anti Infect Ther; 2012 Apr; 10(4):459-73. PubMed ID: 22512755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In-vitro activity of several antimicrobial agents against methicillin-resistant Staphylococcus aureus (MRSA) isolates expressing aminoglycoside-modifying enzymes: potency of plazomicin alone and in combination with other agents.
    López Díaz MC; Ríos E; Rodríguez-Avial I; Simaluiza RJ; Picazo JJ; Culebras E
    Int J Antimicrob Agents; 2017 Aug; 50(2):191-196. PubMed ID: 28577932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plazomicin: A Next-Generation Aminoglycoside.
    Shaeer KM; Zmarlicka MT; Chahine EB; Piccicacco N; Cho JC
    Pharmacotherapy; 2019 Jan; 39(1):77-93. PubMed ID: 30511766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Multicenter, Randomized, Double-Blind, Phase 2 Study of the Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis.
    Connolly LE; Riddle V; Cebrik D; Armstrong ES; Miller LG
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29378708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative in vitro activity of plazomicin and older aminoglyosides against Enterobacterales isolates; prevalence of aminoglycoside modifying enzymes and 16S rRNA methyltransferases.
    Gür D; Hasdemir U; Çakar A; Çavuşoğlu İ; Çelik T; Aksu B;
    Diagn Microbiol Infect Dis; 2020 Aug; 97(4):115092. PubMed ID: 32569921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the Bactericidal Activity of Plazomicin and Comparators against Multidrug-Resistant Enterobacteriaceae.
    Thwaites M; Hall D; Shinabarger D; Serio AW; Krause KM; Marra A; Pillar C
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866876
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Walkty A; Karlowsky JA; Baxter MR; Adam HJ; Zhanel GG
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plazomicin Activity against 346 Extended-Spectrum-β-Lactamase/AmpC-Producing Escherichia coli Urinary Isolates in Relation to Aminoglycoside-Modifying Enzymes.
    López-Diaz MD; Culebras E; Rodríguez-Avial I; Rios E; Viñuela-Prieto JM; Picazo JJ; Rodríguez-Avial C
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27919895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plazomicin Retains Antibiotic Activity against Most Aminoglycoside Modifying Enzymes.
    Cox G; Ejim L; Stogios PJ; Koteva K; Bordeleau E; Evdokimova E; Sieron AO; Savchenko A; Serio AW; Krause KM; Wright GD
    ACS Infect Dis; 2018 Jun; 4(6):980-987. PubMed ID: 29634241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of co-existence of PMQR genes and QRDR mutations on fluoroquinolones resistance in Enterobacteriaceae strains isolated from community and hospital acquired UTIs.
    Kotb DN; Mahdy WK; Mahmoud MS; Khairy RMM
    BMC Infect Dis; 2019 Nov; 19(1):979. PubMed ID: 31752702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece.
    Galani I; Souli M; Daikos GL; Chrysouli Z; Poulakou G; Psichogiou M; Panagea T; Argyropoulou A; Stefanou I; Plakias G; Giamarellou H; Petrikkos G
    J Chemother; 2012 Aug; 24(4):191-4. PubMed ID: 23040681
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of in vitro activities of plazomicin and other aminoglycosides against clinical isolates of Klebsiella pneumoniae and Escherichia coli.
    İnce G; Mirza HC; Üsküdar Güçlü A; Gümüş H; Erol Ç; Başustaoğlu A
    J Antimicrob Chemother; 2021 Nov; 76(12):3192-3196. PubMed ID: 34499728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacodynamics of plazomicin and a comparator aminoglycoside, amikacin, studied in an in vitro pharmacokinetic model of infection.
    Noel AR; Attwood M; Bowker KE; Kim A; Krause KM; MacGowan AP
    Int J Antimicrob Agents; 2019 Nov; 54(5):626-632. PubMed ID: 31299297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between the Presence of Aminoglycoside-Modifying Enzymes and In Vitro Activity of Gentamicin, Tobramycin, Amikacin, and Plazomicin against Klebsiella pneumoniae Carbapenemase- and Extended-Spectrum-β-Lactamase-Producing Enterobacter Species.
    Haidar G; Alkroud A; Cheng S; Churilla TM; Churilla BM; Shields RK; Doi Y; Clancy CJ; Nguyen MH
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5208-14. PubMed ID: 27297487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expected plazomicin susceptibility in India based on the prevailing aminoglycoside resistance mechanisms in Gram-negative organisms derived from whole-genome sequencing.
    Pragasam AK; Jennifer SL; Solaimalai D; Muthuirulandi Sethuvel DP; Rachel T; Elangovan D; Vasudevan K; Gunasekaran K; Veeraraghavan B
    Indian J Med Microbiol; 2020; 38(3 & 4):313-318. PubMed ID: 33154241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro comparison of netilmicin, a semisynthetic derivative of sisomicin, and four other aminoglycoside antibiotics.
    Kabins SA; Nathan C; Cohen S
    Antimicrob Agents Chemother; 1976 Jul; 10(1):139-45. PubMed ID: 825021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of plazomicin against carbapenem-intermediate or -resistant Escherichia coli isolates from the United States and international sites in relation to clonal background, resistance genes, co-resistance, and region.
    Johnston BD; Thuras P; Porter SB; Anacker M; VonBank B; Snippes Vagnone P; Witwer M; Castanheira M; Johnson JR
    J Antimicrob Chemother; 2021 Jul; 76(8):2061-2070. PubMed ID: 34097032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plazomicin for the treatment of patients with complicated urinary tract infection.
    McCarthy MW
    Drugs Today (Barc); 2018 Sep; 54(9):513-518. PubMed ID: 30303492
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can Plazomicin Alone or in Combination Be a Therapeutic Option against Carbapenem-Resistant Acinetobacter baumannii?
    García-Salguero C; Rodríguez-Avial I; Picazo JJ; Culebras E
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5959-66. PubMed ID: 26169398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.